article · Anti-Cancer Agents in Medicinal Chemistry
Researchers evaluated newly synthesised chemical compounds for their potential anti-cancer properties. When tested in laboratory assays, these compounds demonstrated strong cytotoxic activity against PC-3 prostate cancer and MCF-7 breast cancer cell lines, performing favourably in comparison with the standard chemotherapeutic drug 5-fluorouracil. Detailed molecular investigations into specific variants, designated as compounds 11c and 11f, revealed that they bind to the human topoisomerase I enzyme in a manner comparable to known inhibitors. Furthermore, these two compounds significantly suppressed the DNA relaxation activity of human topoisomerase I in a dose-dependent fashion. This specific enzyme inhibition provides a clear molecular mechanism that helps explain how these agents exert their cell-killing effects on the tested cancer cells.
Identifying new molecules that can effectively stop cancer cell growth is crucial for expanding therapeutic options. By targeting human topoisomerase I, an enzyme essential for cellular replication, these newly synthesised compounds show promise in attacking prostate and breast cancer cells, potentially guiding the design of alternative treatments that match or exceed the performance of established drugs.
The findings are relevant to pharmaceutical companies and drug discovery teams developing targeted cancer therapies. These compounds serve as early-stage chemical leads for inhibiting human topoisomerase I in breast and prostate cancers. The work represents early laboratory research, meaning substantial preclinical testing, chemical optimisation, and clinical evaluation would be required before any potential commercial deployment.
AI-generated from the published abstract. Always read the original work before citing.
The newly synthesized compounds showed good activity against PC-3 and MCF-7 cell lines in comparison with 5-fluorouracil. Compounds 11c and 11f bound with human topoisomerase I similar to its known inhibitors and significantly inhibited its DNA relaxation activity in a dose dependent manner which may rationalize their molecular mechanism as cytotoxic agents.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2174/1871520618666171129213838
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
